about
Nutrition and adult inflammatory bowel diseaseProbiotics and medical nutrition therapyIn vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordoniiAssociation of beta-glucan endogenous production with increased stress tolerance of intestinal lactobacilliInduction by a lactic acid bacterium of a population of CD4(+) T cells with low proliferative capacity that produce transforming growth factor beta and interleukin-10.Relationship between pouch microbiota and pouchitis following restorative proctocolectomy for ulcerative colitis.Etiopathogenesis of inflammatory bowel disease: the importance of the pediatric perspective.The role of the gut flora in health and disease, and its modification as therapy.Alternatives to antibiotic use: probiotics for the gut.Gamma interferon augments the intracellular pathway for lipopolysaccharide (LPS) recognition in human intestinal epithelial cells through coordinated up-regulation of LPS uptake and expression of the intracellular Toll-like receptor 4-MD-2 complex.Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis.Intestinal microflora as a therapeutic target in inflammatory bowel disease.Commensal Escherichia coli reduces epithelial apoptosis through IFN-alphaA-mediated induction of guanylate binding protein-1 in human and murine models of developing intestine.Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance.The bacteriology of pouchitis: a molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing.Dietary Keratan Sulfate from Shark Cartilage Modulates Gut Microbiota and Increases the Abundance of Lactobacillus spp.Probiotics and their fermented food products are beneficial for health.Non-digestible oligosaccharides with prebiotic properties.Proposed model: mechanisms of immunomodulation induced by probiotic bacteria.Probiotics in the United States.Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease.Lymphocyte homing and its role in the pathogenesis of IBD.The new prophylactic strategy for colon cancer in inflammatory bowel disease by modulating microbiota.Escherichia coli Nissle 1917 distinctively modulates T-cell cycling and expansion via toll-like receptor 2 signaling.Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats.Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment.Effects of probiotic on intestinal mucosa of patients with ulcerative colitis.Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment.Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice.New Lactobacillus acidophilus isolates reduce the release of leptin by murine adipocytes leading to lower interferon-gamma production.Efficacy of a synbiotic supplementation in the prevention of common winter diseases in children: a randomized, double-blind, placebo-controlled pilot study.Lactobacillus casei prevents the upregulation of ICAM-1 expression and leukocyte recruitment in experimental colitis
P2860
Q22250970-C7494EFC-A07D-4BD0-94AC-5BC6BB04BF82Q24548441-77A112B0-8925-4258-903E-EBCAB4DF38D6Q24804214-607EF25B-A1D3-4267-B7C9-965435B7DAB7Q33585577-34ADFE46-C29B-4E20-951C-A626DC1E1667Q33999211-2B0DF1C0-3031-48F5-ACF6-F078BC6482E2Q34008761-C16DEA56-B3BD-400A-B835-AE713459F1B5Q34538014-56AEE57E-2307-46B5-B1EA-AF0BC4E29B6AQ34786696-454D7243-10EB-420B-A67E-7CB8DE7C10BCQ34815137-CC69DB3A-D960-4857-9179-72FCC46B0BBDQ35011477-9E8FBC48-AFE4-487C-94FC-1E322B3978F5Q35059717-951B3D0F-3DBE-440E-B0F0-212B7E011E8AQ35062098-431058D4-9888-499A-A533-463B932FCF03Q35132878-77F65258-0663-49FE-B6C5-7E5F5663A77AQ35595783-22FC2760-3CF8-4E2B-B42B-9E0A27A396FCQ35799373-C71CE285-D81D-4653-BDC4-2B3E92F66872Q36219804-C612496C-9963-4DE0-A6A5-D4AEFC7DD8B2Q36476720-E547412E-AE16-4BF2-891C-EE2127EAEF98Q36545386-85DA1931-8EFD-44CD-99B6-D1FBA99A6891Q36759892-183B36B6-EA26-4A8B-85C1-471366C902FAQ37053058-9E99818F-4326-4B4C-9707-2D21E29B8505Q37082773-EAD8884F-B366-4BB5-AFB6-EEC5456D8B59Q37130397-5FB8A627-0691-4153-A815-9A17D81324ACQ38068230-29C42A2F-D52F-4EF4-BDD4-C96D2B50FEC2Q42704864-169D1729-CBA0-434B-BD07-0B109D96BF80Q42844036-71EBFA9E-E71A-4858-8D23-9D08E5F55B54Q43005855-B9D7E5BA-BE28-4210-AF38-457C13E627F8Q43159889-1726363A-EC82-460E-837A-C04BBDBF5362Q43746137-C8A62543-EA2A-4097-B2A1-6CAAA9B391A7Q50081572-9EA1C173-0A70-4B1F-8219-74A15E6EDA71Q51445664-7B4AC9E3-379B-430F-BDCC-D89B15B98D11Q51755112-EB84918E-1563-4789-A2DE-B74A3C3CE339Q57241181-060E3205-5B31-45A4-BA11-699F52BFEA2E
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Probiotics and inflammatory bowel diseases.
@ast
Probiotics and inflammatory bowel diseases.
@en
type
label
Probiotics and inflammatory bowel diseases.
@ast
Probiotics and inflammatory bowel diseases.
@en
prefLabel
Probiotics and inflammatory bowel diseases.
@ast
Probiotics and inflammatory bowel diseases.
@en
P1476
Probiotics and inflammatory bowel diseases.
@en
P2093
P304
P356
10.1016/S0002-9270(99)00812-6
P407
P433
P577
2000-01-01T00:00:00Z